Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $791.77 million. The enterprise value is $805.72 million.
Important Dates
The next estimated earnings date is Thursday, July 31, 2025, before market open.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 669.05 million shares outstanding. The number of shares has increased by 2.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 669.05M |
| Shares Change (YoY) | +2.22% |
| Shares Change (QoQ) | -9.59% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 669.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.47 |
| Forward PS | 3.02 |
| PB Ratio | 3.68 |
| P/TBV Ratio | 10.54 |
| P/FCF Ratio | 155.49 |
| P/OCF Ratio | 130.14 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 47.53, with an EV/FCF ratio of 158.23.
| EV / Earnings | n/a |
| EV / Sales | 2.51 |
| EV / EBITDA | 47.53 |
| EV / EBIT | 59.80 |
| EV / FCF | 158.23 |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.55.
| Current Ratio | 2.76 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 5.86 |
| Debt / FCF | 23.40 |
| Interest Coverage | 1.10 |
Financial Efficiency
Return on equity (ROE) is -6.78% and return on invested capital (ROIC) is 2.38%.
| Return on Equity (ROE) | -6.78% |
| Return on Assets (ROA) | 1.99% |
| Return on Invested Capital (ROIC) | 2.38% |
| Return on Capital Employed (ROCE) | 4.14% |
| Revenue Per Employee | $793,832 |
| Profits Per Employee | -$34,931 |
| Employee Count | 404 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 0.61 |
Taxes
In the past 12 months, Pharming Group has paid $10.63 million in taxes.
| Income Tax | 10.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.57% in the last 52 weeks. The beta is 0.54, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +22.57% |
| 50-Day Moving Average | 9.15 |
| 200-Day Moving Average | 8.69 |
| Relative Strength Index (RSI) | 55.86 |
| Average Volume (20 Days) | 3,291 |
Short Selling Information
| Short Interest | 1,301 |
| Short Previous Month | 1,622 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.39 |
Income Statement
In the last 12 months, Pharming Group had revenue of $320.71 million and -$14.11 million in losses. Loss per share was -$0.02.
| Revenue | 320.71M |
| Gross Profit | 285.37M |
| Operating Income | 13.47M |
| Pretax Income | -15.41M |
| Net Income | -14.11M |
| EBITDA | 16.95M |
| EBIT | 13.47M |
| Loss Per Share | -$0.02 |
Full Income StatementBalance Sheet
The company has $107.27 million in cash and $119.14 million in debt, giving a net cash position of -$11.87 million or -$0.02 per share.
| Cash & Cash Equivalents | 107.27M |
| Total Debt | 119.14M |
| Net Cash | -11.87M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 215.29M |
| Book Value Per Share | 0.32 |
| Working Capital | 136.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.08 million and capital expenditures -$992,000, giving a free cash flow of $5.09 million.
| Operating Cash Flow | 6.08M |
| Capital Expenditures | -992,000 |
| Free Cash Flow | 5.09M |
| FCF Per Share | $0.01 |
Full Cash Flow StatementMargins
Gross margin is 88.98%, with operating and profit margins of 4.20% and -4.40%.
| Gross Margin | 88.98% |
| Operating Margin | 4.20% |
| Pretax Margin | -1.14% |
| Profit Margin | -4.40% |
| EBITDA Margin | 5.29% |
| EBIT Margin | 4.20% |
| FCF Margin | 1.59% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.22% |
| Shareholder Yield | -2.22% |
| Earnings Yield | -1.78% |
| FCF Yield | 0.64% |
Analyst Forecast
The average price target for Pharming Group is $30.00, which is 167.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.00 |
| Price Target Difference | 167.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 9.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.19 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.19 |
| Piotroski F-Score | 6 |